Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Evotec Se (OP: EVOTF )

8.980 -0.870 (-8.83%)
Streaming Delayed Price Updated: 1:04 PM EDT, Jun 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 182
Open 8.980
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 9.850
Today's Range 8.980 - 8.980
52wk Range 8.980 - 25.48
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Evotec Announces Progress in Strategic Neuroscience Partnership with Bristol Myers Squibb
Via ACCESSWIRE
Apple Loses Appeal Over 4G Patent Infringement In London Court, AI Can Drive TSMC's Revenue Rebound, Alibaba Conducts Strategic Review of Youku and Tudou Amidst Rivalry: Today's Top Stories
Reuters 
Via Benzinga

Performance

YTD
-58.58%
-58.58%
1 Month
N/A
N/A
3 Month
-11.79%
-11.79%
6 Month
-63.51%
-63.51%
1 Year
-61.95%
-61.95%

More News

Read More
Evotec Secures US Government Contract For Orthopoxvirus Antibody
Via Benzinga
Adapsyn Bioscience Inks Collaboration Pact With Evotec
Via Benzinga
The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate
Via Benzinga
Evotec Enters a Drug Discovery Collaboration with Janssen
From Evotec SE
Via AccessWire
Evotec and Almirall Enter into a Multi-Target Alliance in Medical Dermatology
From Evotec AG
Via AccessWire
Evotec SE Fiscal Year 2021 Results: 'Setting the Pace' on the Data-Driven R&D Autobahn to Cures
From Evotec AG
Via AccessWire
Evotec Achieves Programme Designation in Neuroscience Collaboration with Bristol Myers Squibb
From Evotec AG
Via AccessWire
Why Are Evotec Shares Trading Lower On Friday?
Via Benzinga
Evotec Receives € 7.5 m Grant for Development of COVID-19 Therapeutic
From Evotec AG
Via AccessWire
Exposures COVID-19
Germany Based Evotec Sets Terms For $576M US IPO
Via Benzinga
Pasithea, Evotec Ink Drug Development Pact
Via Benzinga
Evotec Expands Neuroscience Collaboration with Bristol Myers
Via Benzinga
Bristol Myers Exercises Option In-License Evotec's Neurodegenerative Candidate
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.